DSM to sell APIs made by Indoco Remedies

Published: 1-Feb-2012
Ingredients

Part of the planned global expansion of DSM


DSM Pharmaceutical Products (DPP) is to sell eight active pharmaceutical ingredients (APIs) manufactured by Indian firm Indoco Remedies of Mumbai, India, in a new agreement that is a step forward in DSM’s planned global expansion.

The APIs are used in the production of pharmaceutical finished dosages.

‘This is a step in our announced strategy to accelerate growth via partnerships and expansion in Asia to build a product portfolio alongside our custom manufacturing operations, supplying access to high demand treatments,’ said Alexander Wessels, president and chief executive of DSM Pharmaceutical Products.

‘It allows DPP to build a competence base in India.’

Indoco Remedies’ chairman and md Suresh Kare added: “Today in the era of alliances and partnerships, organisations are coming together to penetrate and capture a larger share of the potential opportunities in the market place. Indoco is active in forging such alliances and this one with DSM is a step in that direction.’

  • Companies:
  • Indoco Remedies
  • dsm-firmenich
See more

You may also like

Ingredients

The roadmap to success in the cannabinoid drug development journey

Read more
The key to success in the development and registration of cannabinoid-based medicines hinges on choosing a GMP-certified high-purity active ingredient that is of natural origin and supported by regulatory documentation. Drug developers looking to take product development further still should also consider patient-centricity during formulation and strategies to boost the efficacy of cannabinoids by optimising their bioavailability profile

Trending Articles

  1. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  2. Carbosynth Limited
  3. Highly potent APIs: Hazards in classification and handling This variability and subjective nature of classification means that the OEL is best considered as a tool for site risk management teams
  4. Shasun Chemicals and Drugs Limited
  5. Innovative new process used to produce a diabetes and weight loss drug Camilla Koller, Marketing Communications Associate, tells Dr Kevin Robinson how Bachem has used its extensive experience and expertise in peptide synthesis to develop a fully synthetic method of producing liraglutide at an industrial scale

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Ingredients

The roadmap to success in the cannabinoid drug development journey

The key to success in the development and registration of cannabinoid-based medicines hinges on choosing a GMP-certified high-purity active ingredient that is of natural origin and supported by regulatory documentation. Drug developers looking to take product development further still should also consider patient-centricity during formulation and strategies to boost the efficacy of cannabinoids by optimising their bioavailability profile
Ingredients

What role can CBD play to support mental health?

Talking to Dr Kevin Robinson (KSR), DSM’s Clinical Project Scientist, Mariana Coelho (MC), shares the latest scientific findings behind CBD and how it could help to support mental health and well-being on a global scale, especially as the demand for viable treatments continues to grow
Ingredients

CBD: the new frontier in medical science

Early stage drug development plays an important role in expanding treatment options that will support the health of patients globally. To create bespoke drug products, it is important to explore and understand the benefits of new actives emerging on the market, such as cannabidiol (CBD), explains Kelsey Achenbach, Senior Director, Pharma and Medical Nutrition at DSM
Ingredients

Humanetics acquires all legal assets of DSM radioprotective API

All patents, trademarks, trade secret manufacturing processes of the API for BIO 300 have been sold to US-based Humanetics
Ingredients

DSM at CPhI: the rapidly evolving role of vitamins and lipids in disease management

Royal DSM, a global science-based company active in nutrition, health and sustainable living, invites you to discover the evolving role of vitamins and lipids in pharmaceutical applications at CPhI Worldwide 2018
Ingredients

The increasing importance of drug-nutrient interactions

Emerging scientific evidence suggests that micronutrient intake in higher doses holds promise for roles beyond currently recognised health effects for selected individuals and population groups
Ingredients

DSM at CPhI: the rapidly evolving role of vitamins and lipids in disease management

Royal DSM (stand 7B10), a global science-based company active in nutrition, health and sustainable living, invites you to discover the evolving role of vitamins and lipids in pharmaceutical applications at CPhI Worldwide 2018
Subscribe now